Avidity Biosciences, Inc. (RNAM)

Feb 27, 2026 - RNAM was delisted (reason: acquired by NVS)

71.36

0.00 (0.00%)

Inactive · Last trade price on Feb 26, 2026

144.73% (1Y)

Market Cap	11.07B +174.6%
Revenue (ttm)	18.76M +72.1%
Net Income	-684.63M
EPS	-4.97
Shares Out	155.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,835,884
Open	72.75
Previous Close	n/a
Day's Range	72.75 - 73.04
52-Week Range	21.51 - 73.06
Beta	0.93
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 27, 2026

About RNAM

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company’s pipeline has three programs in clinical development, such as Delpacibart zotadirsen which is in Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular d... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2012

Employees 511

Stock Exchange NASDAQ

Ticker Symbol RNAM

Website https://www.aviditybiosciences.com

Full Company Profile

Financial Performance

In 2025, Avidity Biosciences's revenue was $18.76 million, an increase of 72.11% compared to the previous year's $10.90 million. Losses were -$684.63 million, 112.4% more than in 2024.

Financial Statements